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Abstract 
Epidemiologic evidence indicates that exposure to heterocyclic amines (HAs) in the diet 
is an important risk factor for the development of colon cancer. Well-done cooked meats 
contain significant levels of HAs which have been shown to cause cancer in laboratory 
animals. To better understand the mechanisms of HA bioactivation in humans, the most 
mass abundant HA, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), was used 
to assess the relationship between PhIP metabolism and DNA adduct formation. Ten 
human volunteers where administered a dietary relevant dose of [14C]PhIP 48-72 h prior 
to surgery to remove colon tumors. Urine was collected for 24 h after dosing for 
metabolite analysis, and DNA was extracted from colon tissue and analyzed by 
accelerator mass spectrometry for DNA adducts. All ten subjects were phenotyped for 
CYP1A2, NAT2, and SULT1A1 enzyme activity. Twelve PhIP metabolites were 
detected in the urine samples. The most abundant metabolite in all volunteers was N-
hydroxy-PhIP-N2-glucuronide. Metabolite levels varied sifnificantly between the 
volunteers. Interindividual differences in colon DNA adducts levels were observed 
between each individual. The data showed that individuals with a rapid CYP1A2 
phenotype and high levels of urinary N-hydroxy-PhIP-N2-glucuronide, had the lowest 
level of colon PhIP-DNA adducts. This suggests that glucuronidation plays a significant 
role in detoxifying N-hydroxy-PhIP. The levels of urinary N-hydroxy-PhIP-N2-
glucuronide were negatively correlated to colon DNA adduct levels. Although it is 
difficult to make definite conclusions from a small data set, the results from this pilot 
study have encouraged further investigations using a much larger study group. 
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Introduction 
Humans are constantly exposed to a wide range of chemical carcinogens in their 
environment. One of the most significant sources of environmental exposure is through 
the diet (1). Heterocyclic amines (HAs), formed during the cooking of muscle meats have 
been determined to be mutagenic in standard test systems and carcinogenic in animal 
models (2). These compounds are found in concentrations of up to 500 ppb in foods 
commonly consumed in a typical Western diet. 2-Amino-1-methyl-6-phenylimidazo[4,5-
b]pyridine (PhIP), the most mass abundant HA found in well-done cooked chicken and 
beef (3, 4), has been shown to cause colon, mammary, and prostate tumors in rats, 
lymphomas in mice and hepatic adenomas in neonatal mice (5-8). In humans, 
epidemiology studies have indicated an increased risk of colon and breast tumors 
associated with PhIP exposure from well-done red meat consumption (9, 10). PhIP has 
also been designated as “reasonably anticipated to be a human carcinogen” by the 
National Toxicology Program. These findings, together with the relative abundance of 
PhIP in cooked foods, suggests that exposure to PhIP is a significant cancer risk factor for 
humans. 
Heterocyclic amines require metabolic activation to a bio-reactive species before 
they can interact with DNA to form adducts. The bioactivation of PhIP to its carcinogenic 
species is highly dependent on the cytochrome P4501A2-mediated hydroxylation of the 
exocyclic amine group to form the corresponding 2-hydroxyamino-1-methyl-6-
phenylimidazo[4,5-b]pyridine (N-hydroxy-PhIP) (11, 12). Subsequent esterification by 
sulfotransferases and/or acetyltransferases generates the highly electrophilic O-sulfonyl 
and O-acetyl esters, respectively. These esters are capable of covalently binding DNA 
(13, 14). N-Hydroxy-PhIP can also form the less reactive glucuronide conjugates at the 
N2 amine nitrogen or the N3 ring nitrogen which can be excreted through the urine or 
bile, or be transported to other tissue were further metabolism can occur (15, 16). This 
pathway is a predominant step in the biotransformation of PhIP in humans (17). 
Studies have shown that the rate of HA metabolism can be influenced by enzyme 
phenotype and/or genotype. A correlation between cytochrome P4501A2 (CYP1A2) 
activity levels and urinary excretion of HA metabolites was observed in human 
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populations fed well-done cooked meat. High levels of CYP1A2 activity was associated 
with reduced levels of unmetabolized PhIP in the urine, indicating more PhIP is being 
converted to the bioactive N-hydroxy derivative compared to urinary HA levels from 
individuals with low CYP1A2 activity (18-20). In addition, polymorphisms in the UDP-
glucuronosyltransferase 1A1 (UGT1A1) gene was associated with a decreased ability to 
detoxify N-hydroxy-PhIP via glucuronidation in human liver samples due to reduced 
UGT1A1 activity (21). 
Enzyme polymorphisms can lead to interindividual variation in DNA adduct 
formation as well. A positive correlation was reported between the level of DNA adducts 
and the level of CYP1A2 activity in human liver microsomes incubated with PhIP. As 
CYP1A2 activity increased there was a concomitant increase in PhIP-DNA adduct levels. 
These results indicate that DNA adducts can be used as an indicator of interindividual 
variability in the metabolic activation of HAs (22). 
Increases in bioactivation and DNA adduct formation due to enzyme 
polymorphisms have been implicated as increased cancer risk factors associated with HA 
exposure. For example, phenotypic differences in CYP1A2 and N-acetyltransferase 2 
(NAT2) activity have been linked to colon cancer risk. People who possess the rapid 
phenotype for both enzymes and consume high levels of dietary HAs have been shown to 
be at a greater risk to develop colon cancer than people who possess the slow phenotype 
(23). Therefore, susceptibility to the carcinogenic risks associated with HA exposure can 
depend on exposure levels, as well as, specific enzyme phenotypes that can effect the 
bioactivating capacity of certain metabolizing enzymes. 
The relationship between PhIP-DNA adduct formation, metabolism, and exposure 
has been primarily established at high PhIP doses using animal models, mostly due to 
limitations in assay sensitivity and the difficulties associated with human in vivo studies. 
In the present study these limitations have been overcome by using accelerator mass 
spectrometry (AMS), which is capable of accurately measuring attomole (10-18) 
quantities of radiolabeled compound (24, 25). The goal of the current study is to 
determine the relationship between PhIP metabolism, DNA adduct levels, and enzyme 
phenotype in humans, at a dietary relevant dose of PhIP, and to determine if metabolite 
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levels and/or enzyme phenotype can predict interindividual susceptibility to DNA adduct 
formation. 
Accelerator mass spectrometry was used to measure colon DNA adducts in a 
human population exposed to a dietary equivalent dose of PhIP, labeled with a very low 
level of 14-carbon. The 0.011mSv radioactive dose each subject received is equivalent to 
1/29 of the energy received from an average chest x-ray. Urinary PhIP metabolite levels 
and selected enzyme phenotypes were also assessed in an effort to establish a link 
between metabolite levels, enzyme phenotype, and DNA adducts. Data is presented that 
suggests urinary PhIP metabolite levels can serve as a biomarker to predict 
interindividual differences in DNA adduct levels at dose levels that are typical of human 
exposure conditions. This pilot study should provide a better understanding of the critical 
role each metabolic step has in the bioactivation and detoxification of this carcinogen. 
Ultimately, an assessment of individual susceptibility to the potential cancer risks from 
PhIP exposure should be possible.  
 
Materials and Methods 
Chemicals. [2-14C]PhIP was obtained from Toronto Research Chemicals (North York, 
Ontario, Canada). After repurification the chemical purity was > 99% and the radiopurity 
was > 95%. Qiagen tip-500 anion exchange columns for DNA extractions were obtained 
from Qiagen (Valencia, CA). Proteinase K, Rnase A and Rnase T1 were purchased form 
Sigma Chemical Co. (St. Louis O). All other reagents were of analytical grade or better. 
 
Human Study. The human study protocol was independently reviewed and approved by 
the Institutional Review Boards for Human Subjects at the Lawrence Livermore National 
Laboratory, the University of Arkansas Medical School Hospital, and the J.L. McClellan 
Memorial Veterans Administration Medical Center in Little Rock AR.  Details of the 
study protocol are reported elsewhere (26). Briefly, ten human volunteers were recruited 
for the study. All volunteers were undergoing surgery to remove colon carcinoma(s) and 
gave informed consent prior to enrollment. The study population consisted of 9 
Caucasian males and 1 Caucasian female ranging in age from 44-82 yrs. [14C]PhIP was 
administered orally in a gelatin capsule prior to surgery. Subjects 1 and 2 received a dose 
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of 70 µg [14C]PhIP per person (specific activity, 56 mCi/mmol), and subjects 3-10 
received a dose of 84 µg [14C]PhIP (specific activity 41.8 mCI/mmol). The differences in 
the amounts and the specific activity of [14C]PhIP were a result of preparing the PhIP 
capsules on two different occasions from two batches of [14C]PhIP. 
 
Urinary Metabolite Characterization. Urine was collected at various time points up to 
24 h after [14C]PhIP exposure and then frozen at –20°C until processing for metabolite 
analysis. Details of the urinary metabolite analysis have been previously reported (17). 
Briefly, an aliquot of each urine sample containing approximately 6000-8000 DPM was 
analyzed by HPLC for PhIP and PhIP metabolites. Each sample was directly injected into 
a Rainin HPLC system (Varian, Walnut Creek, CA) equipped with a 5 µm, 4.6 x 220 mm 
TSK-GEL ODS-80 TM column (TosoHaas, Montgomeryville, PA), and monitored at 315 
nm. The column eluate was collected at 1-minute intervals and radioactivity was 
quantified by scintillation counting (Wallic, Gaithersburg, MD). Metabolites were 
identified by co-elution with authentic PhIP metabolite standards and by mass spectral 
characterization (17). For mass spectral analysis each isolated metabolite was directly 
injected into a Michrom µLC system (Michrom Bioresources Inc., Auburn, CA) 
equipped with a Zorbax C18 SB column (0.2 x 150 mm) (Michrom Bioresources Inc., 
Auburn, CA) and coupled to a Finnigan MAT TSQ-700 triple quadrupole mass 
spectrometer through a Finnigan electrospray interface (Finnigan MAT, San Jose, CA). 
Full scan and collision induced dissociation (CID) mass spectra were obtained for each 
metabolite, using previously described parameters (17). 
 
Tissue Collection and DNA Extraction. Forty-eight to seventy-two hours after dosing 
the volunteers underwent surgery for a partial colonectomy. Colon tissue not required for 
diagnosis or staging was collected and frozen at –80°C until analysis. DNA and protein 
was extracted from the colon tissue and analyzed by AMS for PhIP-adduct formation 
using previously reported methods (26, 27). 
 
Enzyme Phenotyping. Blood was collected prior to [14C]PhIP dosing for phenotyping 
sulfotransferase 1A1 (SULT1A1) activity. Separation of platelets and preparation of 
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cytosol for SULT1A1 phenotyping has been described previously (28). Phenotyping for 
CYP1A2 and N-acetyltransferae 2 (NAT2) was done pre- or post-operatively using the 
caffeine phenotyping assay (29, 30). 
 
Statistical Analysis. Two statistical approaches were used to analyze the data. The first 
utilized univariate linear modeling, and stepwise variable selection using the Akaike 
Information Criterion (AIK), method. These parametric methods were used because of 
the small number of degrees of freedom (df = 9) available in this study. Since there were 
26 variables (Table 5) but only ten observations in the study, and the degrees of freedom 
in a linear model is df = n - p, where n is the number of observations, and p is the number 
of parameters or variables, a model including all 26 variables could not be fitted. 
The second approach, used the nonparametric Random Forest Regression 
analysis, developed by Breiman and Cutler 
(http://www.stat.berkeley.edu/users/breiman/RandomForest/), which is a test to 
determine the importance of one variable in relation to another. This method ranks all 
variables in a study in the order of importance. The importance measure, which is the 
percent increase in Mean Squared Error (MSE), is calculated for each variable. Each 
variable is then randomly shuffled across observations, while all other variables are left 
as is. The new MSE is calculated using the Random Forest Regression algorithm. If the 
variable in question is an important predictor of the outcome (i.e. DNA adducts), the new 
calculated MSE will be higher than the original MSE. The larger the percent increase in 
MSE, the more important the variable is as a predictor of outcome. 
 
Results 
Urinary Metabolite Analysis. The total amount of radioactivity recovered in the urine 
over 24 h varied among the ten individuals, ranging between 32-85% of the administered 
dose (Figure 1). Part of this variation may be due to inconsistencies in the sample 
labeling from subjects 2 and 9, non-continuous sampling from subject 3, and fecal 
contamination in the urine from subject 8. Therefore, no further conclusions were made 
from these observations. However, the amount of recovered urinary radioactivity also 
varied over time. In subjects 1, 4, 7, 8 and 10 over 45% of the total amount of recovered 
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radioactivity was excreted in the first 4 h after [14C]PhIP dosing. In subjects 2, 3, 5, 6, 
and 9, the majority of radioactivity was recovered in the later time periods (Figure 2). 
All ten volunteers produced 12 radioactive metabolite peaks associated with PhIP 
from the first 24 h of collected urine. Identification of the major urinary PhIP metabolites 
from a subset of these individuals has been previously reported (17), and is presented in 
Table 1. Six of the twelve metabolites were identified as PhIP glucuronide conjugates. In 
all ten subjects the amount of PhIP-glucuronide metabolites accounted for 60-85% (Table 
2) of the total metabolites indicating that in humans, glucuronidation is a major pathway 
in the biotransformation of PhIP. 
The most abundant PhIP metabolite in all ten volunteers was determined to be N-
hydroxy-PhIP-N2-glucuronide. The amount of this metabolite varied greatly between 
individuals, accounting for 37-62% of the total amount of recovered urinary metabolites 
(Table 2). Excretion rates for this metabolite also varied significantly between each 
subject (Figure 3). In five out of the ten subjects over 45% of N-hydroxy-PhIP-N2-
glucuronide was excreted in the first four hours after PhIP dosing, with subject 4 being 
the highest at 63% excreted in 4 h. Subject 2 had the lowest at 19% excreted in 4 h. 
Metabolites 1, 2, and 3 (all of which have been tentatively identified as PhIP-glucuronide 
conjugates) displayed a wide range of variability between the ten subjects as well, each 
accounting for 0.6-8% of the total amount of recovered metabolites. No other metabolites 
displayed such a wide range of variability between the subjects. Interestingly, in subjects 
where N-hydroxy-PhIP-N2-glucuronide was present at greater than 50% of the total 
recovered metabolites, the cumulative total of metabolites 1, 2, and 3 was less than 7% of 
the total recovered metabolites. Whereas, when N-hydroxy-PhIP-N2-glucuronide levels 
were below 50% of the total recovered metabolites, the cumulative total of metabolites 1, 
2, and 3 ranged between 8-20% (Table 2). These results suggest that the enzymes 
involved in catalyzing the formation of these metabolites may be in competition with 
each other for substrate. 
 
DNA and Protein Adduct Analysis. The levels of covalently bound [14C]PhIP in colon 
DNA and protein, and total [14C] levels in whole tissue are presented in Table 3. 
Interindividual differences were evident in the amount of PhIP bound to all three tissue 
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fractions. There was no correlation, however, between the binding levels of PhIP in DNA 
and the levels in the protein or tissue within each individual. Only subject six displayed a 
consistent binding pattern, having the highest level of [14C]PhIP in DNA, total protein, 
and whole tissue compared to the rest of the study group. Blood albumin was also 
collected and assessed for covalent binding of [14C]-PhIP. There was no correlation 
between albumin adducts and the colon DNA, protein, or tissue adducts (data not shown). 
 
Phenotype Analysis. Each subject was phenotyped for CYP1A2, NAT2, and SULT1A1 
enzyme activity.  All of which are known to be involved in PhIP metabolism. Table 4 
shows the phenotypic activity levels for CYP1A2, NAT2, and SULT1A1 for the ten 
subjects. The CYP1A2 and NAT2 activities, estimated from the caffeine metabolism 
phenotyping assay, showed a dichotomized distribution. CYP1A2 activity levels greater 
that 10 were categorized as having a rapid CYP1A2 phenotype, and values less than 10 
were considered a slow metabolizer, based on the analysis of the caffeine metabolite 
ratios (31). Subject 4 had the highest CYP1A2 activity with a value nearly three times 
higher then the next highest value in subject 1. The NAT2 values were also divided into 2 
groups: a slow group with caffeine metabolite ratios less than 0.66 and a fast group with 
ratios greater than O.66 (31). Based on this criterion, subjects 1, 4, 5, 9, and 10 were 
labeled as having a rapid NAT2 phenotype. Only two subjects, (subject 6 and subject 8) 
were considered to have fast SULT1A1 activity levels when the phenotype values were 
dichotomized at 1.0 nmol/min/mg protein (32). 
 
Statistical Analysis. Data obtained from the metabolite analysis, enzyme phenotype, and 
PhIP-adduct data sets were analyzed by various statistical methods to determine if any of 
the measured variables were correlated to colon DNA adducts. There were twenty-six 
variables that were considered for this analysis. Both univariate and non-parametric 
models were used to evaluate the data. Since there were 26 variables but only 9 degrees 
of freedom it was not possible to fit a full univariate linear model to include all the 
variables. Therefore, a univariate linear analysis was done for each variable and the p-
values were compared from each analysis. Table 5 shows the univariate linear model 
results for all the variables. N-Hydroxy-PhIP-N2-glucuronide, metabolite 7, and CYP1A2 
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activity had the lowest p-values indicating these variables are the most significantly (p < 
0.05) correlated to colon DNA adducts. However, the low level, and the lack of 
significant variation in metabolite 7 between each subject deemed this metabolite not 
useful for predicting DNA adducts. N-Hydroxy-PhIP-N2-glucuronide was determined to 
be the best predictor of colon DNA adducts. Because of the low degrees of freedom due 
to the small sample set, the data was independently re-evaluated using the non-parametric 
Random Forrest analysis. Although this is a less robust test compared to the univariate 
analysis, the two independent tests provided the same apparent conclusion that N-
hydroxy-PhIP-N2-glucuronide was the most important variable in predicting the level of 
PhIP-DNA adducts in the colon. 
Linear regression analysis showed that both N-hydroxy-PhIP-N2-glucuronide 
levels in the urine and CYP1A2 activity were negatively correlated with the level of 
PhIP-DNA adducts in the colon. A higher level of N-hydroxy-PhIP-N2-glucuronide in the 
urine and a rapid CYP1A2 phenotype was associated with lower levels of colon PhIP-
DNA adducts (Table 6). 
 
Discussion 
This study has allowed, for the first time, a comprehensive assessment of PhIP 
metabolism and DNA adduct formation in humans at a dietary relevant dose of PhIP. The 
use of radiolabeled PhIP and AMS technology allowed for the quantification of urinary 
metabolites and colon DNA adducts at levels that are consistent with a typical dietary 
exposure. The findings from this pilot study is consistent with earlier data showing that 
PhIP urinary metabolites and DNA adducts are formed in significant quantities even from 
a low dose exposure of PhIP (17, 26). The present study reports on variations in PhIP 
metabolite excretion and DNA adduct formation within a small study population of ten 
human volunteers. The data suggests there is a significant correlation between urinary 
metabolite levels and colon DNA adducts. 
Interpretation of the results from this study must take into account that the human 
subject volunteers were elderly cancer patients undergoing colorectal cancer surgery. 
Each subject was taking numerous medications prior to surgery for a number of 
conditions. Furthermore, the PhIP dose they received was administered in capsule form 
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and was not part of the diet. These factors could have influenced the disposition of PhIP 
in these subjects. 
Six of the twelve PhIP metabolites were identified as glucuronide conjugates 
indicating that glucuronidation plays a significant role in the metabolism of PhIP. The 
identification of N-hydroxy-PhIP-N2-glucuronide as the major urinary metabolite in all 
ten subjects is consistent with earlier studies showing UGT1A1-mediated glucuronidation 
as being a major pathway in the biotransformation of PhIP (33). The presence of this 
metabolite also serves as an indirect indicator of PhIP bioactivation, since formation of 
the CYP1A2-mediated reactive intermediate N-hydroxy-PhIP is a prerequisite step to 
forming N-hydroxy-PhIP-N2-glucuronide (15, 16). These results are contrary to what has 
been reported for rodents. In both rats and mice N-hydroxy-PhIP-N2-glucuronide is a 
minor urinary metabolite. The major metabolite in the rodent is 4’-PhIP-sulfate indicating 
that hydroxylation at the 4’ ring position (a detoxification step) followed by conjugation 
by sulfotransferase is more prevalent in rodents than in humans (34, 35). This could be 
due to differences in substrate selectivity and oxidation rates of the different CYP450 
isozymes between humans and the rodent model. Consequently, these differences will 
make it difficult to make accurate extrapolations from rodent data to humans. 
The finding that glucuronidation is a major detoxification pathway in the 
biotransformation of PhIP is significant because the capacity to glucuronidate N-
hydroxy-PhIP can vary greatly among individuals due to genetic polymorphisms in the 
UGT1A1 gene. The most notable polymorphisms are variants in the UGT1A1 gene that 
result in significant down regulation of UGT1A1 activity. The most prevalent 
polymorphism is characterized by an allelic variant in the UGT1A1 gene which contains 
an additional (TA) dinucleotide repeat in the “A(TA)nTAA” box region of the promoter 
(36). Wild-type UGT1A1 activity is associated with six repeats whereas the variant allele 
contains seven TA repeats (UGT1A1*28). Significant down regulation of UGT1A1 
activity results when this variant is present in both alleles (homozygous). The frequency 
of occurrence is relatively high at 10-12% of the general population. There is evidence to 
suggest that individuals with the UGT1A1*28 genotype may be at greater risk for cancer 
from exposure to HAs that are conjugated by UGT1A1 because their ability to detoxify 
these compounds would be diminished (37). For example, a recent study has reported a 
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correlation between the UGT1A1*28 polymorphism and a decreased ability to 
glucuronidate and detoxify N-hydroxy-PhIP in human liver microsomes (21). Samples 
derived from subjects who were homozygous for the UGT1A1*28 allelic variant showed 
significant decreases in UGT1A1 protein expression and N-hydroxy-PhIP 
glucuronidation activity in liver microsomes when compared to samples derived from 
subjects having the wild-type UGT1A1*1 genotype. 
To determine if the observed variations in metabolism and DNA adducts from the 
current study population were due to variations in UGT1A1 expression, each individual 
was genotyped for the UGT1A1*28 polymorphism. Seven out of the nine individuals 
tested were heterozygous (6/7) for the “A(TA)nTAA” repeat. The remaining two subjects 
were homozygous wild-type (6/6). Previous studies have shown that there is no 
significant difference in UGT1A1 activity between the wild-type and the heterozygous 
variant (38, 39). Only individuals possessing the homozygous variant (7/7) display 
significant down regulation of UGT1A1 activity. Therefore, due to the lack of significant 
UGT1A1 genotype variation, and the homogeneity of the study population, UGT1A1 
genotype would not be expected to influence the metabolism or the DNA adduct profiles 
of these individuals. Additional experiments, using a larger study population, are needed 
to determine the role of UGT1A1 activity on PhIP-DNA adduct formation. 
The differences in urinary PhIP metabolite levels, metabolite excretion rates, and 
DNA and protein adducts between the study subjects suggests that interindividual 
phenotypic variation of specific enzymes associated with PhIP biotransformation may be 
contributing to these observed variations. Although it is difficult to make any definite 
conclusions from the data due to the small sample size, several trends in metabolite 
excretion rates, DNA adduct levels and enzyme phenotypes were observed. Subjects 1, 4, 
and 7, who were categorized as having a rapid CYP1A2 phenotype, had the lowest level 
of [14C]PhIP bound to colon DNA. These subjects also had the fastest excretion rate and 
the highest levels of urinary N-hydroxy-PhIP-N2-glucuronide after 24 h of collection, 
suggesting detoxification of N-hydroxy-PhIP predominated over bioactivation. These 
observations are in agreement with the linear regression analysis that showed both N-
hydroxy-PhIP-N2-glucuronide and CYP1A2 activity were negatively correlated to colon 
DNA adducts. Furthermore, the univariate analysis showed that N-hydroxy-PhIP-N2-
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glucuronide levels and CYP1A2 phenotype were also the most important variables in 
predicting colon DNA adduct levels.  
Subjects 8 and 10 also had rapid excretion rates of N-hydroxy-PhIP-N2-
glucuronide, although, these individuals were categorized as having a slow CYP1A2 
phenotype. These two subjects, however, did have a UGT1A3*3 genotype (unpublished 
data), which is associated with increased expression of UGT1A3 (40). The increased 
expression of UGT1A3 could have contributed to an increase in the formation of N-
hydroxy-PhIP-N2-glucuronide (33). In another observation subject 6 had the highest level 
of PhIP macromolecular adducts in all three endpoints (DNA, total protein and whole 
tissue), and was the only subject with both NAT2 and SULT1A1 rapid phenotypes. 
Statistical analysis however, indicated there was no correlation (p < 0.05) between the 
NAT2 or SULT1A1 phenotype and DNA adduct levels. Furthermore, the differences 
among each individual in the time the colon tissue was harvested after [14C]PhIP 
exposure and the relative rate of DNA repair could have influenced DNA adduct levels. 
Further study is needed to determine if these observations are relevant to human cancer 
risk. Other variables that were excluded from analysis, due to the lack of relevance to 
PhIP metabolite levels and DNA adducts, were CYP1A1, NAT1 and glutathione-S-
transferase genotypes (data not shown). 
The finding that colon DNA adducts were lower in subjects with a rapid CYP1A2 
phenotype and higher urinary N-hydroxy-PhIP-N2-glucuronide levels suggests that 
detoxification by glucuronidation predominated over bioactivation in these individuals. 
This was somewhat unexpected since Lang et al. reported a correlation between rapid 
CYP1A2 and rapid NAT2 activity with a higher incidence of colon cancer among 
individuals who consume heterocyclic amines in their diet (23). However, Sachse et al. 
reported that CYP1A2 activity was lower in colon cancer patients compared to controls 
(41). These findings suggests that DNA adducts alone may not be good predictors of 
cancer incidence. The low levels of adducts and high N-hydroxy-PhIP-N2-glucuronide 
levels observed in rapid CYP1A2 individuals seen in this present study could partially be 
explained by the differences in the Km and Vmax values for CYP1A2 and UGT1A1, as 
well as the phase II activation enzymes (i.e. acetyltransferase and/or sulfotransferase). 
High levels of N-hydroxy-PhIP-N2-glucuronide indicates that the reactive intermediate, 
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N-hydroxy-PhIP, was detoxified by glucuronidation at a faster rate compared to 
conjugation by acetyltransferase and/or sulfotransferase, which results in further 
activation to the DNA binding species. Therefore, it can be postulated that individuals 
with compromised UGT activity may be at greater risk from exposure to PhIP than 
individuals with normal or elevated levels of UGT because their ability to detoxify PhIP 
will be diminished. These results are consistent with the present understanding of PhIP 
metabolism (42). 
Based on the above observations, and from the statistical analysis of the data it 
was determined that out of all the variables investigated, N-hydroxy-PhIP-N2-glucuronide 
was the best predictor of colon DNA adducts. The subjects with high levels of N-
hydroxy-PhIP-N2-glucuronide in their urine had the lowest level of PhIP-DNA adducts in 
their colon. This is the first time a urinary biomarker has been linked to a genotoxic 
endpoint. These conclusions must be made with caution, however, since they are based 
on a small study group that may not be representative of the general population. 
Nevertheless, this pilot study has provided some insight into the disposition of PhIP in a 
human population at a dietary relevant dose, and has served as a basis for continual study 
to determine if N-hydroxy-N2-glucuronide can serve as a reliable urinary biomarker to 
predict an individual’s propensity to form colon DNA adducts. 
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Table 1. Identity of Urinary Radioactive HPLC Peaks Associated with PhIP  
Peak 
no. 
HPLC rt 
(min) 
m/z 
[M +H]+ * 
Metabolite peak 
assignment 
1 20 417.1/241/225 PhIP-glucuronide† 
2 22 417.1/241/225 OH-PhIP-glucuronide† 
3 27 417.1/241/225 OH-PhIP-glucuronide† 
4 32 n/a Unknown 
5 36 n/a Unknown 
6 41 320.3/240.9/224.9 4’-SO4-PhIP 
7 45 n/a Unknown 
8 50 401.3/224.9 PhIP-N2-glucuornide 
9 52 417/241/225.1 N2-OH-PhIP-N2-glucuronide 
10 57 417/225.1 N2-OH-PhIP-N3-glucuornide 
11 62 n/a N2-OH-PhIP† 
12 65 225 PhIP 
*LC/MS/MS analysis showing parent and fragment ions; n/a=not available 
†Tentative identification 
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Table 2. PhIP metabolites recovered from human urine in 24 h after a14C-PhIP dose* 
 
 
Subject Number 
metab. 
no.† 
1 2 3 4 5 6 7 8 9 10 
1 0.0 6.3 1.8 1.1 3.1 3.4 0.8 2.7 1.2 1.3 
2 0.6 5.6 2.7 3.1 6.2 7.9 1.6 4.6 4.8 2.1 
3 0.0 7.9 3.5 2.8 7.2 6.0 1.8 5.2 5.6 2.4 
4 0.7 0.0 1.2 1.4 1.0 0.7 1.9 1.0 1.4 1.4 
5 0.0 3.7 1.0 0.7 1.0 1.8 0.9 0.8 1.6 0.9 
6 7.9 6.1 10.0 7.3 10.3 5.5 6.5 7.6 7.4 4.0 
7 1.2 2.0 2.3 1.1 2.1 1.8 1.1 1.7 1.8 1.2 
8 6.5 9.0 3.8 4.3 7.0 10.7 4.1 8.0 7.4 7.2 
9 61.4 47.3 37.2 56.8 45.7 47.7 62.3 48.3 47.4 59.7 
10 8.6 8.1 9.6 7.5 7.9 9.6 8.4 9.6 6.4 11.0 
11 7.3 2.8 7.6 6.2 5.5 2.4 6.8 5.8 9.3 5.2 
12 0.7 1.2 0.6 0.4 0.6 0.5 0.4 0.6 0.7 0.3 
*Data is expressed as percent of recovered urinary radioactivity in 24 h 
†See Table 2 for metabolite identity 
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Table 3. Covalent binding of [14C]PhIP to colon DNA and protein, and total [14C] 
 levels in whole tissue* 
 
Subject no. DNA Total protein Whole tissue 
1 30.25 ± 2.3 67.44 ± 1.4 41.97 ± 7.9 
2 49.99 ± 2.6 107.73 ± 1.8 133.95 ± 27.4 
3 97.24 ± 7.3 98.32 ± 1.2 77.22 ± 7.3 
4 26.14 ± 3.9 183.09 ± 48.9 92.39 ± 35.0 
5 50.96 ± 11.0 66.45 ± 0.8 58.09 ± 19.0 
6 119.34 ± 2.5 398.85 ± 86.2 279.29 ± 68.9 
7 34.55 ± 4.2 266.51 ± 87.5 42.76 ± 15.3 
8 71.19 ± 1.8 223.57 ± 6.9 259.99 ± 72.4 
9 100.85 ± 1.0 247.84 ± 4.2 169.84 ± 1.2 
10 45.25 ± 2.7 138.16 ± 2.5 67.09 ± 40.1 
*Data are expressed as pg PhIP/g DNA, protein or whole tissue ± the standard deviation 
of at least 3 measurements. 
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Table 4. CYP1A2, NAT2, and SULT1A1 Phenotype data 
 
Subject no. CYP1A2* NAT2† SULT1A1‡ 
1 17.0 0.77 0.71 
2 2.27 0.62 0.36 
3 7.49 0.62 0.56 
4 48.92 3.12 0.87 
5 6.11 2.25 0.64 
6 1.99 2.56 3.52 
7 12.67 0.28 0.31 
8 4.48 0.28 1.83 
9 2.85 2.48 0.83 
10 2.04 2.41 0.46 
*CYP1A2 activity is the urinary molar ratio of [17U + 17X]/137X, where 137X 
[caffeine] is 1,3,7-trimethylxanthene, [17U] is 1,7-dimethyluric acid, and [17X] is 1,7-
dimethylxanthene. 
†NAT2 activity is the urinary molar ratio of AFMU/1X, where AFMU is 5-acetylamino-
6-formylamino-3-methyluracil and 1X is 1-methylxanthine.  
‡SULT1A1 activity is expressed as nmol/min per mg protein. 
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Table 5. Univariate linear model results from all variables for outcome related to DNA 
adduct levels. Variables are listed in order of decreasing importance in relation to DNA 
adduct levels. 
Variable Estimate Std. Error t value p value FDR adjusted p value* 
N-OH-PhIP-N2-gluc. -2.75 0.94 -2.93 0.02 0.27 
metabolite 7 48.47 17.97 2.70 0.03 0.27 
CYP1A2 activity -46.09 17.68 -2.61 0.03 0.27 
albumin adducts T.02 h -0.11 0.05 -2.29 0.05 0.34 
subject age delta 1.74 0.85 2.05 0.07 0.35 
albumin adducts T.04 h -0.23 0.12 -1.90 0.09 0.35 
metabolite 2 7.50 3.92 1.91 0.09 0.35 
SULT1A1 activity 40.86 23.46 1.74 0.12 0.4 
albumin adducts T.005 h -0.07 0.05 -1.39 0.2 0.49 
albumin adducts T.01 h -0.04 0.03 -1.39 0.2 0.49 
metabolite 3 5.87 4.02 1.46 0.18 0.49 
Area under curve -0.02 0.01 -1.24 0.25 0.52 
metabolite 5 15.78 13.36 1.18 0.27 0.52 
PhIP-N2-gluc. 5.57 4.91 1.14 0.29 0.52 
time to surgery 3 -30.50 24.64 -1.24 0.26 0.52 
albumin adducts T.24 h 0.06 0.06 0.87 0.41 0.69 
metabolite 1 4.24 6.25 0.68 0.52 0.83 
albumin adducts T.08 h 0.07 0.12 0.60 0.57 0.86 
albumin adducts T.12 h 0.02 0.08 0.25 0.81 0.95 
metabolite 4 -8.51 21.72 -0.39 0.71 0.95 
N-OH-PhIP-N3-gluc. 2.21 8.69 0.25 0.81 0.95 
metabolite 11 -1.73 5.42 -0.32 0.76 0.95 
time to surgery 2 -12.55 28.23 -0.44 0.67 0.95 
4’-PhIP-sulfate 1.03 6.52 0.16 0.88 0.96 
PhIP 4.27 47.82 0.09 0.93 0.96 
NAT2 activity -1.11 22.49 -0.05 0.96 0.96 
subject weight -0.01 0.19 -0.05 0.96 0.96 
*False discovery rate adjusted p value 
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Table 6. Relationship between CYP1A2 phenotype, urinary N-OH-PhIP-N2-glucuronide 
levels, and colon DNA adduct levels 
    Subject number    
 1 2 3 4 5 6 7 8 9 10 
CYP1A2 
phenotype Fast Slow Slow Fast Slow Slow Fast Slow Slow Slow 
           
N-OH-PhIP- 
N2-gluc.* 61.3 47.3 37.2 56.7 45.7 47.6 62.3 48.2 47.3 59.6 
           
DNA 
adducts† 30.2 49.9 97.2 26.1 50.9 119.3 34.5 71.2 100.8 45.25 
*Data is expressed as percent of recovered radioactivity 
†Data is expressed as pg PhIP/g DNA 
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Figure Legends 
Figure 1. The percent of radioactivity recovered in the urine of each subject in 24 h after 
an oral [14C]PhIP dose. Data is expressed as percent of administered dose. 
 
Figure 2. Radioactivity levels in human urine over time after an oral [14C]PhIP dose. Data 
is expressed as percent of excreted radioactivity in 24 h. 
*collection time was 0-4 h, 4-12 h, 12-24 h; **collection time was 0-4 h, 4-17.5 h, 17.5-
33 h. 
 
Figure 3. Rate of N-hydroxy-PhIP-N2-glucuronide excreted in human urine after an oral 
[14C]PhIP dose. Data is expressed as percent of N-hydroxy-PhIP-N2-glucuronide excreted 
over time ± the standard deviation. Each subject was analyzed three times. 
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Malfatti et al. Figure 1 
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Malfatti et al. Figure 2 
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